What question did this study set out to answer?

This research aims to evaluate lipid nanoparticles as a delivery method for gene editing in human hematopoietic stem cells to enhance resistance to CAR-T cell therapy.

December 8, 2025BloodOpen Access

Lipid nanoparticle-mediated epitope editing in human HSPCs enables resistance to CD45-directed CAR-T cell therapy

View Full Paper

Ask AI

Bookmark

Authors

EGElahe Kamali GhaheParker Institute for Cancer Immunotherapy DTDavin TafuriParker Institute for Cancer Immunotherapy RDRujul Jagdish DeolikarParker Institute for Cancer Immunotherapy

Discussion

Member takes

Implication

Comparative analysis reveals lipid nanoparticles preserve HSPC viability and engraftment similar to electroporation during CD45 editing for CAR-T therapy.

Key Points

This research aims to evaluate lipid nanoparticles as a delivery method for gene editing in human hematopoietic stem cells to enhance resistance to CAR-T cell therapy.
Compared editing efficiency of a base editor delivered via lipid nanoparticles or electroporation in human HSPCs.
Assessed the impact of delivery methods on HSPC viability, multi-lineage differentiation, and engraftment in immunodeficient mice.
Used human CD34⁺ HSPCs modified with a guide RNA targeting CD45 epitope for the editing process.
Lipid nanoparticles achieved a 1.5-fold increase in cell recovery compared to electroporation.
Editing efficiencies were comparable: 95% for electroporation and 81% for lipid nanoparticles before transplantation.
Both methods supported long-term engraftment and multilineage hematopoiesis in bone marrow of primary recipients.

Cite This Study

Ghahe et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d43a https://doi.org/10.1182/blood-2025-1048

View Full Paper

Ask AI

Bookmark

Implication

Comparative analysis reveals lipid nanoparticles preserve HSPC viability and engraftment similar to electroporation during CD45 editing for CAR-T therapy.

Lipid nanoparticle-mediated epitope editing in human HSPCs enables resistance to CD45-directed CAR-T cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Lipid nanoparticle-mediated epitope editing in human HSPCs enables resistance to CD45-directed CAR-T cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider